Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Seagate Technology Holdings PLC (STX) Price & Performance

Regeneron Pharmaceuticals IncTrade
Seagate Technology Holdings PLCTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Seagate Technology Holdings PLC — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Seagate Technology Holdings PLC trades at $887 (market cap $205.65B). The key difference: Seagate Technology Holdings PLC is far larger — about 2.5× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.46%). Which is the better fit depends on your goals.

REGNSTX
Market Cap
$83.43B$205.65B
Sector
HealthTechnology
52-Week High
$852.03$1.09K
52-Week Low
$555.51$193.04
Enterprise Value
$78.14B$207.80B
Dividend Yield
0.46%0.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Seagate Technology Holdings PLC

Seagate Technology (STX) trades at $904.38, up 6.49% today, with strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with support at $868 and resistance at $933. Recent earnings beats and robust 2026 revenue guidance of $12.2B highlight fundamental strength, though valuation ratios remain elevated with P/E at 65.06. Analyst consensus is bullish with a $1,130 price target, supported by institutional accumulation and positive media coverage of HAMR technology adoption.

Outlook: STX benefits from AI-driven storage demand and operational execution, but faces risks from high debt and competitive pressures. The stock's premium valuation requires sustained growth to justify upside. Near-term catalysts include Q3 earnings and product ramps, while macroeconomic volatility and execution missteps pose headwinds. Investor sentiment remains positive, but caution is warranted given rich multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Seagate Technology Holdings PLC

Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital

Read more on STX